Tuesday, 12 Nov 2019

You are here

CIRT Trial - Methotrexate Fails at Cardiovascular Prevention

Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.

The CIRT trial was prematurely halted in April 2018 as the Data Safety Monitoring Board judged that MTX was unable to  prevent CV events and that continuation would not likely favorably change these outcomes.

The study was published in the NEJM and presented at American Heart Association meeting in Chicago.

The large Cardiovascular Inflammation Reduction trial (CIRT) was funded by the NHLBI and halted based on a recommendation from the trial's Data and Safety Monitoring Board. This was a cardiovascular intervention trial and did not involve patients with RA or arthritis. 

This was a randomized, double-blind trial of low-dose MTX (escalated to 15 to 20 mg weekly) vs. placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease (stable atherosclerosis) who additionally had either type 2 diabetes or the metabolic syndrome. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death or unstable angina that led to urgent revascularization.

After 2.3 years the trial was stopped. The primary endpoint occurred equally in those treated with MTX (n=201) or placebo (n=207) (hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). At the final visit, the mean MTX dose was roughly 19 mg/week but roughly 1 in 5 patients had permanently discontinued the trial regimen.

Compared with placebo, MTX treated patients had more liver enzyme elevations, leukopenia, higher MCV values, more  anemia and non–basal-cell skin cancers. MTX patients also had more oral ulcers and unintended weight loss. 

Additionally MTX did not significantly lower interleukin-1β, interleukin-6, or C-reactive protein levels than placebo. 

These findings are surprising in light of the success of the CANTOS trial wherein canakinumab (an IL-1 inhibitor) significantly lowered CV events in high risk CV patients. 

One difference between trials is that the CANTOS trial enrolled patients with a prior myocardial infarction and elevated high sensitivity C-reactive protein (CRP) of 2.0 mg/L or more.  The mean entry CRP levels were lower in CIRT compared to CANTOS (~1.5 vs 4.5 mg/L) and statins were used by >85% of patients in both trials.  Yet, the CANTOS trial showed canakinumab to lower IL-1 and CRP levels while demonstrating significantly fewer CV events, CVA and cancer deaths.  Nevertheless, the FDA has denied Novartis application to use canakinumab in cardiac prevention by issuing a complete response letter (rejection). 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.